

Patient Name : Mrs. NETU 582
Age/Sex : 24 Y/Female
Patient ID : 012211060004



10012405

Reference : Self
Organization : Pathsquare labs
Org Address :

Registered On : 06/Nov/2022 07:14AM
Collected On : 06/Nov/2022 09:02AM
Reported On : 06/Nov/2022 04:48PM
UHID :

Test Name	Value	Unit	Bio Ref.Interval	Method
-----------	-------	------	------------------	--------

HEMATOLOGY

HB ELECTROPHORESIS (HPLC):EDTA

Specimen: Whole Blood EDTA

Foetal Haemoglobin (HbF)	<0.8	%	0.0 - 2.0	Method: HPLC
Haemoglobin A0 (Hb A0)	97.9	%	94.3 - 98.5	(HPLC, NGSP certified)
Haemoglobin A2 (HbA2)	2.5	%	0 - 3.5	
Haemoglobin D (HbD)	0.00	%	0 - 0	
Haemoglobin S (HbS)	0.00	%	0 - 0	
Haemoglobin C (HbC)	0.00	%	0.0	

Method: HPLC (High performance liquid chromatography), on whole blood.

Interpretations & Remarks:-

1. All results have to be correlated with age and history of blood transfusion If there is history of blood transfusion in last 3 months, repeat testing after 3 months from last date of transfusion is recommended.
2. In case of haemoglobinopathy, parents or family studies and counseling is advised.
3. This test detects Beta thalassaemia and haemoglobinopathies. DNA analysis is recommended to rule out alpha thalassaemia and silent carriers.
4. Linearity range of HbF is 1-40%, however, values in excess of the reportable range have been provided for ease of interpretation.
5. Mild to moderate increase in fetal hemoglobin can be seen in some acquired conditions like Pregnancy, Megaloblastic anaemia, Thyrotoxicosis, Hypoxia, Chronic kidney disease, Recovering marrow, MDS, Aplastic anaemia, PNH, Medications (Hydroxyurea, Erythropoietin) etc.
6. P3 window- Above 10% is often indicative of either denatured forms of hemoglobins or may suggest a possibility of abnormal haemoglobin variant. Hence, repeat analysis with fresh sample or DNA studies is advised.
7. P2 window- Above 10% is indicative of either glycated haemoglobin requiring correlation with diabetic status or may suggest a possibility of abnormal haemoglobin variant requiring further DNA studies for confirmation.

8. Note : This report holds valid only if there is no history of blood transfusion in last 3-6 months

Medical Remark :

This is a screening test. Prenatal Screening and DNA Studies advised for confirmation.

Comment: Impression No Evidence of Beta Thalassemia or Hemoglobinopathy.


*** End Of Report ***




Dr. Shilpa Hastir
MD (Pathology)
Gold Medalist

Patient report

Bio-Rad DATE: 11/06/2022
D-10 TIME: 04:48 PM
S/N: #DJ8H659101 Software version: 4.30-2
Sample ID: 10012405
Injection date 11/06/2022 04:43 PM
Injection #: 7 Method: HbA2/F
Rack #: --- Rack position: 7



Peak table - ID: 10012405

Peak	R.time	Height	Area	Area %
A1a	0.20	4439	15773	0.7
A1b	0.28	6679	28693	1.2
F	0.45	1614	15267	< 0.8 *
LA1c/CHb-1	0.69	2356	18813	0.8
A1c	0.87	8193	81343	4.8
P3	1.50	13543	112794	4.7
A0	1.69	468863	2097538	86.5
A2	3.20	3216	54718	2.5
Total Area:		2424937		

Concentration:	%
F	< 0.8 *
A1c	4.8
A2	2.5